RAPT Therapeutics Reports Second Quarter 2022 Financial Results
Company maintains strong cash position of $207.3 million SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022…
News
Motus GI Regains Compliance with Nasdaq Minimum Bid Price Requirement
FORT LAUDERDALE, Fla., Aug. 11, 2022 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus…
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2022
Menlo Park, California, Aug. 11, 2022 (GLOBE NEWSWIRE) — Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,”…
Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
• UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth…
Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
– Following the recent submission of the IND application for CNTY-101 and pending FDA clearance,…
Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Advancement across Company’s pipeline towards regulatory and data milestones BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE)…
Better Choice Company Reports Record Second Quarter 2022 Gross Sales and Provides Corporate Update
Better Choice Reports Record Second Quarter 2022 Gross Sales of $19.8 Million and Net Sales…
Abeona Therapeutics Reports Second Quarter 2022 Financial Results
Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023…
Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results
Verrica held Type A meeting with the FDA regarding the path forward for the resubmission…
Innovation1 Biotech Appoints Chief Scientific Officer Andrew L. Salzman, M.D. to its Board of Directors
NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) — Innovation1 Biotech Inc. (OTCQB: IVBT) (“Innovation1” or…
Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
WVE-006 announced as investigational development candidate for AATD with CTA submissions expected in 2023; first-in-class RNA…
CorMedix Inc. Reports Second Quarter and Six Month 2022 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, N.J., Aug. 11,…
Aleafia Health Announces $12.0 Million Total Net Revenue in First Quarter, Representing a 13% Increase Over the Prior Year
31% increase in branded cannabis net revenue1 to $10.0 million from $7.6 million in the…
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for…
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
– Topline Data Expected First Quarter 2023 – DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug….
Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
— Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED)…
Bioventus Reports Second Quarter Results; Updates Full-Year 2022 Financial Guidance
DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the…
Vistin Pharma ASA: Invitation to Q2 2022 conference call
Oslo, Norway, 11 August 2022 Vistin Pharma ASA will release its second quarter and YTD…
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights
– FDA granted IND clearance for lead candidate WTX-124 for evaluation as a treatment for…
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
In line with corporate strategy update in April, ProQR to focus exclusively on the development…